The Adaptability of Chromosomal Instability in Cancer Therapy and Resistance.

DNA damage DNA damage response epigenetic changes immune evasion immunotherapy

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Dec 2022
Historique:
received: 26 11 2022
revised: 14 12 2022
accepted: 20 12 2022
entrez: 8 1 2023
pubmed: 9 1 2023
medline: 11 1 2023
Statut: epublish

Résumé

Variation in chromosome structure is a central source of DNA damage and DNA damage response, together representinga major hallmark of chromosomal instability. Cancer cells under selective pressure of therapy use DNA damage and DNA damage response to produce newfunctional assets as an evolutionary mechanism. Recent efforts to understand DNA damage/chromosomal instability and elucidate its role in initiation or progression of cancer have also disclosed its vulnerabilities represented by inappropriate DNA damage response, chromatin changes, andinflammation. Understanding these vulnerabilities can provide important clues for predicting treatment response and for the development of novel strategies that prevent the emergence of therapy resistant tumors.

Identifiants

pubmed: 36613695
pii: ijms24010245
doi: 10.3390/ijms24010245
pmc: PMC9820635
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Immunol. 2010 Nov;11(11):997-1004
pubmed: 20890285
Cell. 2018 May 3;173(4):972-988.e23
pubmed: 29656893
Curr Biol. 2009 Mar 24;19(6):524-9
pubmed: 19268590
Nat Cell Biol. 2018 Aug;20(8):954-965
pubmed: 30022119
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Nat Rev Clin Oncol. 2011 Mar;8(3):151-60
pubmed: 21364688
J Biol Chem. 2001 Nov 9;276(45):42462-7
pubmed: 11571274
Mol Cell. 2007 Dec 28;28(6):1045-57
pubmed: 18158901
Nature. 2012 Aug 23;488(7412):504-7
pubmed: 22820252
Trends Cancer. 2017 Mar;3(3):225-234
pubmed: 28718433
Annu Rev Biochem. 2018 Jun 20;87:263-294
pubmed: 29709199
Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19108-13
pubmed: 19855003
Nature. 2010 Mar 18;464(7287):436-40
pubmed: 20173739
Mol Cancer Res. 2003 Jun;1(8):598-609
pubmed: 12805407
Cancer Res. 2021 Jun 1;81(11):2861-2873
pubmed: 33762357
Cancer Res. 2011 May 15;71(10):3447-52
pubmed: 21270108
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Cancer Res. 2012 Apr 1;72(7):1608-13
pubmed: 22287547
Nature. 2005 Mar 31;434(7033):605-11
pubmed: 15758953
Nat Commun. 2019 Jan 9;10(1):100
pubmed: 30626869
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Nat Struct Mol Biol. 2011 Apr;18(4):510-5
pubmed: 21399641
Gut. 2018 Feb;67(2):348-361
pubmed: 28360097
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nat Rev Mol Cell Biol. 2010 Mar;11(3):220-8
pubmed: 20177397
Mol Cell. 2001 Feb;7(2):263-72
pubmed: 11239455
Annu Rev Biochem. 2019 Jun 20;88:221-245
pubmed: 30917004
Mol Cell Biol. 2010 Jan;30(1):22-32
pubmed: 19841063
Cell Cycle. 2015;14(17):2810-20
pubmed: 26151317
Trends Cancer. 2021 Feb;7(2):98-111
pubmed: 33109489
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
Cancer Res. 2005 Dec 15;65(24):11597-604
pubmed: 16357170
Oncogene. 2018 Apr;37(15):2037-2051
pubmed: 29367762
J Cell Biol. 2007 Mar 12;176(6):749-55
pubmed: 17353355
Nature. 2009 Mar 26;458(7237):461-7
pubmed: 19325626
Nature. 2003 Jan 30;421(6922):499-506
pubmed: 12556884
Cancer Discov. 2013 Jan;3(1):68-81
pubmed: 23103855
Sci Immunol. 2020 Jan 24;5(43):
pubmed: 31980485
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
Sci Rep. 2019 Feb 12;9(1):1853
pubmed: 30755715
Mol Cell. 2020 Oct 1;80(1):21-28
pubmed: 32810436
Mol Cell. 2009 Aug 28;35(4):534-41
pubmed: 19716796
Nat Rev Immunol. 2010 Feb;10(2):123-30
pubmed: 20098460
Nature. 2009 Oct 22;461(7267):1071-8
pubmed: 19847258
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60
pubmed: 19369211
Nat Rev Clin Oncol. 2018 Mar;15(3):139-150
pubmed: 29297505
Sci Signal. 2010 Dec 07;3(151):rs3
pubmed: 21139141
N Engl J Med. 2009 Oct 8;361(15):1475-85
pubmed: 19812404
Cancer Discov. 2017 Mar;7(3):264-276
pubmed: 28031159
Cell Oncol. 2008;30(5):453
pubmed: 18791276
Cancer Res. 2016 Feb 15;76(4):902-11
pubmed: 26837770
Mol Cancer Res. 2009 Jul;7(7):1110-8
pubmed: 19584259
Cell Rep. 2016 Jun 21;15(12):2679-91
pubmed: 27292643
Cancer Res. 2016 Nov 15;76(22):6747-6759
pubmed: 27680683
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
Lancet Oncol. 2017 Aug;18(8):1009-1021
pubmed: 28694034
Nat Rev Cancer. 2020 Aug;20(8):437-454
pubmed: 32581320
Genes Dev. 2001 Dec 15;15(24):3237-42
pubmed: 11751629
Genes Dev. 2007 Dec 15;21(24):3214-31
pubmed: 18079171
Curr Opin Cell Biol. 2005 Dec;17(6):568-75
pubmed: 16226452
Nat Commun. 2019 Jul 17;10(1):3143
pubmed: 31316060
Nat Rev Immunol. 2012 Apr 25;12(5):367-82
pubmed: 22531325
Cell. 2013 Mar 14;152(6):1344-54
pubmed: 23498941
Mol Cell. 1999 Oct;4(4):511-8
pubmed: 10549283
Cancer Res. 2011 Mar 1;71(5):1858-70
pubmed: 21363922
J Hepatol. 2021 Feb;74(2):350-359
pubmed: 32810553
PLoS Pathog. 2015 Jun 29;11(6):e1005030
pubmed: 26121674
N Engl J Med. 2021 Mar 25;384(12):1168-1170
pubmed: 33761214
Science. 2008 Mar 7;319(5868):1352-5
pubmed: 18323444
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
J Biol Chem. 2001 Dec 21;276(51):47755-8
pubmed: 11668173
Cancer Discov. 2019 Jun;9(6):722-737
pubmed: 31015319
Nature. 2008 Feb 28;451(7182):1116-20
pubmed: 18264087
Nature. 2012 Jan 18;482(7383):53-8
pubmed: 22258507
Nature. 2018 Aug;560(7716):117-121
pubmed: 30022168
Mol Cell. 2017 Feb 16;65(4):671-684.e5
pubmed: 28132842
Nat Rev Mol Cell Biol. 2020 May;21(5):284-299
pubmed: 32094664
Nat Struct Mol Biol. 2010 Jun;17(6):688-95
pubmed: 20453858
Mol Cell. 2018 Sep 6;71(5):745-760.e5
pubmed: 30193098
Science. 2013 Feb 8;339(6120):700-4
pubmed: 23306437
Cell Rep. 2016 Jan 12;14(2):282-97
pubmed: 26748708
Cell. 1993 Dec 3;75(5):1027-38
pubmed: 8252616
Cancer Cell. 2018 Jan 8;33(1):125-136.e3
pubmed: 29316426
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):60-65
pubmed: 31152819
J Cell Sci. 2012 Aug 1;125(Pt 15):3529-34
pubmed: 22553214
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5
pubmed: 30540933
Science. 2009 Jan 16;323(5912):401-4
pubmed: 19074313
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325

Auteurs

Vinicio Carloni (V)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50121 Florence, Italy.

Elisa Morganti (E)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50121 Florence, Italy.

Andrea Galli (A)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50121 Florence, Italy.

Antonio Mazzocca (A)

Interdisciplinary Department of Medicine, University of Bari-School of Medicine, 70121 Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH